Herti 150mg Injection

Herti 150 mg Injection contains Trastuzumab, a targeted monoclonal antibody used to treat HER2-positive breast and gastric cancers by specifically binding to the HER2 receptor and blocking cancer cell growth and survival signals. Administered as an intravenous infusion under strict medical supervision, it helps slow tumor progression and improve treatment outcomes. Herti may be given weekly or once every three weeks depending on the therapy plan, with heart function closely monitored during treatment. Common side effects include fever, headache, cough, rash, and infections, while serious risks such as heart or lung problems require immediate medical attention; it is not recommended during pregnancy and should never be self-administered.